Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 631.00 GBp
Change Today +8.50 / 1.37%
Volume 841.6K
BTG On Other Exchanges
Symbol
Exchange
London
Berlin
OTC US
OTC US
As of 11:35 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

btg plc (BTG) Snapshot

Open
623.00 GBp
Previous Close
622.50 GBp
Day High
631.50 GBp
Day Low
616.50 GBp
52 Week High
01/9/15 - 834.50 GBp
52 Week Low
08/24/15 - 556.00 GBp
Market Cap
2.4B
Average Volume 10 Days
601.7K
EPS TTM
0.09 GBp
Shares Outstanding
382.8M
EX-Date
06/7/00
P/E TM
69.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for BTG PLC (BTG)

Related News

No related news articles were found.

btg plc (BTG) Related Businessweek News

No Related Businessweek News Found

btg plc (BTG) Details

BTG plc, a specialist healthcare company, acquires, develops, and commercializes pharmaceutical products worldwide. It operates through three segments: Interventional Medicine, Specialty Pharmaceuticals, and Licensing. The Interventional Medicine segment offers oncology products, including Beads and TheraSphere for the treatment of liver tumours; pulmonology products comprising RePneu Coil system for the treatment of emphysema; and vascular products, such as EkoSonic for severe blood clots, as well as Varithena for moderate to severe varicose veins. The Specialty Pharmaceuticals segment provides acute care and antidote products, such as CroFab for crotalid snakebites; DigiFab for digoxin toxicity; and Voraxaze for high-dose methotrexate toxicity. The Licensing segment offers Abiraterone acetate for advanced prostate cancer; Alemtuzumab for multiple sclerosis; and Two-Part Hip Cup for hip replacement. BTG plc is also developing uridine triacetate that is in late-stage of clinical trials for life-threatening toxic side effects of overexposure to the chemotherapeutic 5-fluorouracil. The company also manufactures and commercializes therapeutic ultrasound devices. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.

1,121 Employees
Last Reported Date: 05/18/15
Founded in 1948

btg plc (BTG) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 1.1M GBP
Chief Financial Officer, Executive Director a...
Total Annual Compensation: 707.0K GBP
Compensation as of Fiscal Year 2015.

btg plc (BTG) Key Developments

Mike Inglis to Join BT as Non-Executive Director and Member of the Technology Committee, Effective September 1, 2015

Mike Inglis is to join the BT Board as a non-executive director and a member of the BT Technology Committee, which was set up in early 2015 to agree the development and implementation of BT s major technology innovation strategies. His appointment takes effect from September 1, 2015. Mike is currently a non-executive director and chairman designate of Ilika. He is also non-executive director of Pace plc and an independent director at Micro Devices. Until March 2013, Mike was on the board of ARM Holdings having joined the company in 2002 and held roles including chief commercial officer, EVP and general manager of the processor division and EVP sales and marketing. Mike also held roles with Texas Instruments, Fairchild and BIS Macintosh and gained his initial industrial experience with GEC Telecommunications.

BTG plc Receives Approval from Health Canada for Varithena

BTG plc announced that Health Canada has issued a Notice of Compliance approving Varithena (polidocanol injectable foam) for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein (GSV) system, above and below the knee. An estimated 3.7 million Canadians have varicose veins, with women twice as likely as men to develop varicosities. Varithena (polidocanol injectable foam) is a uniform, low-nitrogen, polidocanol microfoam, dispensed from a proprietary canister device. Treatment is minimally invasive, non-surgical (no incision) and requires neither tumescent anesthesia nor sedation. Varithena® is intended for use in adults with clinically significant venous reflux as diagnosed by duplex ultrasound and is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the GSV system, above and below the knee. For intravenous use only. Varithena is intended for intravenous injection using ultrasound guidance, administered via a single cannula into the lumen of the target incompetent trunk veins or by direct injection into varicosities. Physicians administering Varithena must be experienced with venous procedures, possess a detailed working knowledge of the use of the duplex ultrasound in venous disease and be trained in the administration of Varithena. The use of Varithena is contraindicated in patients with known allergy to polidocanol and those with acute thromboembolic disease. Severe allergic reactions have been reported following administration of liquid polidocanol, including anaphylactic reactions, some of them fatal. Observe patients for at least 10 minutes following injection and be prepared to treat anaphylaxis appropriately. Intra-arterial injection or extravasation of polidocanol can cause severe necrosis, ischemia or gangrene. Patients with underlying arterial disease, such as marked peripheral arteriosclerosis or thromboangiitis obliterans (Buerger's Disease) may be at increased risk for tissue ischemia. If intra-arterial injection of polidocanol occurs, consult a vascular surgeon immediately. Varithena can cause venous thrombosis. Follow administration instructions closely and monitor for signs of venous thrombosis after treatment. Patients with reduced mobility, history of deep vein thrombosis or pulmonary embolism, or recent (within 3 months) major surgery, prolonged hospitalization, or pregnancy are at increased risk for developing thrombosis. In clinical trials, the most common related adverse events (occurring in =3% of patients treated with Varithena) were pain/discomfort in extremity, infusion site thrombosis (retained coagulum), injection site hematoma or pain, thrombophlebitis superficial, and extravasation.

BTG plc Provides Earnings Guidance for the Fiscal Year 2016

BTG plc provided earnings guidance for the fiscal year 2016. For the year, the company announced that a strong performance in the 2014/15 financial year, the business has made a good start to the current financial year with overall trading in line with expectations. As previously announced, the company's full year revenue is expected to be in the range £410 million to £440 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BTG:LN 631.00 GBp +8.50

BTG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Impax Laboratories Inc $40.96 USD -1.44
Merit Medical Systems Inc $22.75 USD +0.13
Pfizer Ltd/India 2,360 INR +51.10
RPX Corp $13.77 USD -0.06
Medicines Co/The $41.00 USD +7.36
View Industry Companies
 

Industry Analysis

BTG

Industry Average

Valuation BTG Industry Range
Price/Earnings 72.8x
Price/Sales 6.7x
Price/Book 3.3x
Price/Cash Flow 40.5x
TEV/Sales 6.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BTG PLC, please visit www.btgplc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.